Tetsuya Yamagata

Company: Modalis Therapeutics

Job title: Scientific Advisory, CSO

Seminars:

Movement Towards the Clinic: Preclinical Development of Gene Activation Programs with CRISPR-GNDM® Platform 12:00 pm

Demonstrate the efficiency and durability of gene activation by Cas-9 mediated in vivo epigenome editing Understand the impact of using a muscle tropic AAV capsid delivery system Highlight that despite sustained Cas-9 expression and limited immunogenicity, favorable toxicology data support the therapeutic safety profileRead more

day: Day Two